Abstract

The necessity of determining and assessing the dynamics of albuminuria and glomerular filtration rate in patients with type 1 and type 2 DM (as an early marker of endothelial dysfunction and a predictor of cardiovascular complications) was substantiated amid pathogenetic therapy with glycosaminoglycan sulodexide. There is a clinically significant decrease in the levels of both total protein and albumin in the urine, which along with an increase in glomerular filtration rate indicates an improvement in renal microcirculation. It is worth pointing out that the increase in glomerular filtration rate is mostly evident among type 2 DM patients with comorbid non-alcoholic fatty liver disease.

Keywords: Diabetes Mellitus; Albuminuria; Endothelial Dysfunction; Non-alcoholic Fatty Liver Disease; Treatment

References

1. A Dei Cas., et al. “Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure”. JACC Heart Fail 3 (2015): 136-145.
2. D Aguilar., et al. “Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus”. American Journal of Cardiology 105 (2010): 373-377.
3. P A McCullough., et al. “Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference”. Nephrology Dialysis Transplantation 25 (20132:010): 1777-1784.
4. McAliste F A., et al. “Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials”. Journal of the American College of Cardiology 44 (2004): 810-819.
5. G Ronco., et al. “Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative”. European Heart Journal 31 (2010): 703-711.
6. Sinha A., et al. “Costs and consequences associated with newer medications for glycemic control in type 2 diabetes”. Diabetes Care 33 (2010): 695-700.
7. P H Bennett., et al. “Screening and management of microalbuminuria in patients with diabetes mellitus”. American Journal of Kidney Diseases2 (1995): 107-112.
8. 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. “Canadian Diabetes Association Clinical Practice Guidelines Expert Committee of the Canadian Diabetes Advisory Board”. Canadian Diabetes Association. Canadian Journal of Diabetes 37 (2013): 212.
9. J Koskinen., et al. “Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young finns study”. Circulation3 (2009): 229-236.
10. Bramlage P., et al. “Clinical practice and recent recommendations in hypertension management-reporting a gap in a global survey of 1259 primary care physicians in 17 countries”. Current Medical Research and Opinion 23 (2007): 783-791.
11. P Bramlage., et al. “A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients”. Journal of Clinical Hypertension9 (2010): 666-677.
12. A Must., et al. “The disease burden associated with overweight and obesity”. JAMA 282 (1999): 1523-1529.
13. F Vanmolkot and J de Hoon. “Endothelial function in migraine: a cross-sectional study”. BMC Neurology 10 (2010): 119.
14. J S Jensen., et al. “Microalbuminuria is associated with a fourfold increased risk of ischemic heart disease among hypertensive patients”. Ugeskr Laeger32 (2002): 3773 - 3777.
15. K Wachtell., et al. “Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study”. Annals of Internal Medicine 139 (2003): 901-906.
16. M H Olsen., et al. “N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study”. Journal of Hypertension8 (2004): 1597-1604.
17. The Heart Outcome Prevention Evaluation Study Investigators. “Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients”. The New England Journal of Medicine 342 (2000): 145-153.
18. L Vaur., et al. “Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study”. Diabetes Care 3 (2003): 855-860.
19. H L Hillege., et al. “Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group”. Circulation 14 (2002): 1777-1782.
20. H L Hillege., et al. “Renal function as a predictor of outcome in a broad spectrum of patients with heart failure”. Circulation 5 (2006): 671-678.
21. S Shohaimi., et al. “Occupational social class, educational level and area deprivation independently predict plasma ascorbic acid concentration: a cross-sectional population based study in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk)”. European Journal of Clinical Nutrition 10 (2004): 1432-1435.
22. K Klausen., et al. “Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes”. Circulation 1 (2004): 32-35.
23. A D Liese., et al. “Microalbuminuria, central adiposity and hypertension in the non-diabetic' urban population of the MONICA Augsburg survey 1994/95”. Journal of Human Hypertension 15 (2001): 799-804.
24. M B Moss., et al. “Platelet aggregation in arterial hypertension: is there a nitric oxide-urea connection?”. Clinical and Experimental Pharmacology and Physiology2 (2010): 167-172.
25. Dzau VJ. “Tissue Angiotensin and Pathobiology of Vascular Disease”. Hypertension 37 (2001): 1047.
26. Cai H., et al. “Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress”. Circulation Research 87 (2000): 840.
27. J Galle and K Heermeier. “Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress”. Nephrology Dialysis Transplantation 14 (1999): 2585-2589.
28. Harrison D G. “Endothelial function and oxidant stress”. Clinical Cardiology 20 (1997): 11-17.
29. M E Pueyo., et al. “Angiotensin II Stimulates Endothelial Vascular Cell Adhesion Molecule-1 via Nuclear Factor B Activation Induced by Intracellular Oxidative Stress”. Arteriosclerosis, Thrombosis, and Vascular Biology 20 (2000): 645.
30. Seely EW. “Hypertension in pregnancy: a potential window into long-term cardiovascular risk in women”. The Journal of Clinical Endocrinology and Metabolism6 (1999): 1858-1861.
31. A S Zakaria., et al. “Effects of gastric banding on glucose tolerance, cardiovascular and renal function, and diabetic complications: a 13-year study of the morbidly obese”. Surgery for Obesity and Related Diseases 15 (2015): 1550-7289.
32. R M van Dam., et al. “Coffee consumption and incidence of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes: the Hoorn Study”. Diabetologia 47 (12) (2004): 2152-2159.
33. Gambaro G., et al. “Glycosaminoglycans: use in treatment of diabetic nephropathy”. Journal of the American Society of Nephrology 2 (2000): 359-368.
34. Gaddi A V., et al. “Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered”. International Journal of Nephrology and Renovascular Disease 3 (2010): 99-105.
35. A Połubińska., et al. “Sulodexide modifies intravascular homeostasis what affects function of the endothelium”. Advances in Medical Sciences2 (2013): 304-310.
36. Hoppensteadt DA., et al. “Pharmacological profile of sulodexide”. International Angiology3 (2014): 229-235.
37. R Li., et al. “Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review”. Drug Design, Development and Therapy 9 (2015): 6275-6283.
38. A S Levey and L A Stevens. “Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions”. American Journal of Kidney Diseases4 (2010): 622-627.

Citation

Citation: IP Dunaieva., et al. “Albuminuria as an Independent Factor of Cardiovascular Complications in Patients with Comorbid Pathology". Acta Scientific Cardiovascular System 1.6 (2022): 02-09.

Copyright

Copyright: © 2022 IP Dunaieva., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.